CGEM

Cullinan

--

--(--)

Market Open: --

--

--(--)

Post-Market: --

Signals Analysis

Buy signal 1

Sell signal 1

consensus rating "Strong Buy"

EPS Below Expectations

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

--

Prev.Close

--

%Range

--

Turnover

--

Avg Vol(4W)

--

Market Cap

--

Div.Yield

--

P/E(TTM)

--

EPS(TTM)

--

Beta

--

Free Float

--

Shares Outstanding

--

%Turnover

--

P/E(DYN)

--

P/B

--

BVPS

--

High

--

Low

--

52 Week High

--

52 Week Low

--

About CGEM

Cullinan Therapeutics, Inc.

A biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer

Industry

Pharmaceutical

Established Date

Invalid Date

Listing Date

01/08/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

111

Fiscal Year Ends

12-31

Website

www.cullinantherapeutics.com

Security Type

Common stock

Office address

One Main Street, Suite 520, Cambridge, MA 02142

Business

--

Introduction

Cullinan Therapeutics, Inc., is incorporated in Delaware. The company is a biopharmaceutical company focused on developing a diverse pipeline of tumor-targeted therapies and immuno-oncology therapies with translational potential for cancer patients.

Company Financials

EPS

CGEM has released its 2024 Q4 earnings. EPS was reported at -0.73, versus the expected -0.74, beating expectations. The chart below visualizes how CGEM has performed over recent quarters, highlighting trends in earnings surprises.